EMA Authorised: Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma) (dabigatran etexilate mesilate) — Teva GmbH

View source ↗

Summary

The EMA authorised Teva's dabigatran etexilate mesilate product for prevention of venous thromboembolism, including after arthroplasty (joint replacement).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Dabigatran etexilate Teva (dabigatran etexilate mesilate)

Snippet

Status: Authorised. Therapeutic area: Venous Thromboembolism;Arthroplasty, Replacement. MAH: Teva GmbH. Decision date: 20/01/2025